The duration of 10 years following the marketing authorization of an orphan medicine, during which similar medicines intended for the same indication are prohibited from entering the market.
Confounding by Indication
Contact our experts today
Composed of proven experts from the pharmaceutical industry, our team is ready to answer to your needs in any
area of product development, commercialisation and early access programs, and life cycle management